Writing in the journal NanoResearch, a team at the University of Massachusetts Amherst reports that they have developed bioelectronic ammonia gas sensors that are among the most sensitive ever made. The sensor uses electric-charge-conducting protein nanowires derived from the bacterium Geob ... more
Animal testing methods for endocrine disruptors should change, team argues
Review suggests that oral gavage, the accepted method of dosing lab animals to test chemical toxicity, does not accurately mimic how humans are exposed to chemicals in everyday life
Challenging risk assessment methods used for decades by toxicologists, a new review of the literature led by environmental health scientist Laura Vandenberg at the University of Massachusetts Amherst suggests that oral gavage, the most widely accepted method of dosing lab animals to test chemical toxicity, does not accurately mimic how humans are exposed to chemicals in everyday life.
Oral gavage refers to the way researchers give chemicals to animals by putting a tube down their throats to deliver substances directly to the stomach. It has been used for decades and is at present the dosing scheme preferred for assessing potential toxicity of endocrine disrupting chemicals (EDC) by regulatory agencies.
Vandenberg, with colleagues at the University of Missouri-Columbia and Université de Toulouse, France, writes, "We conclude that gavage may be preferred over other routes for some environmental chemicals in some circumstances, but it does not appropriately model human dietary exposures for many chemicals. Because it avoids exposure pathways, is stressful and thus interferes with endocrine responses, gavage should be abandoned as the default route of administration for hazard assessments of EDCs."
Though gavage does offer precise dose and timing control, the authors say it is not appropriate for assessing EDCs, using Bisphenol A (BPA) as a primary example. Its drawbacks include the fact that gavage bypasses the mouth, which means animals experience "dramatic differences in absorption, bioavailability and metabolism" than humans experience when eating food, which is thought to be way most people are exposed to BPA. Further, gavage carries well-known risks including perforation of the esophagus that diminish its value.
Finally, the authors point out that the gavage protocol itself can induce stress responses in the endocrine system, which may confound EDC assessment. "We propose the exploration of alternatives to mimic human exposures when there are multiple exposure routes/sources and when exposures are chronic," they urge. Their work appears in Environmental Health.
Vandenberg and colleagues say they chose BPA because exposure is widespread in humans, low doses have been linked to adverse effects in laboratory animals, exposure is linked to a wide range of human diseases, and unanswered questions remain about how best to model exposure routes and sources. The lack of detailed understanding of all potential routes of exposure applies to many chemicals used in a wide range of products, they add.
The researchers reviewed more than 60 papers and reports, pointing out that "for hypothesis testing, route of exposure may not be of central importance, but for hazard assessment, risk assessors typically require that studies use a route of exposure that is deemed 'relevant' to humans."
They point to recent studies in dogs and monkeys where scientists could study different BPA absorption when it was administered both by mouth and by traditional gavage. Given to dogs under the tongue, BPA entered into circulation largely in an unconjugated form, that is, without having been converted to an inactive form by the liver in so-called first-pass metabolism. By comparison, over 99 percent of the BPA was metabolized rapidly in the dogs with gavage. Similarly, less than 1 percent of administered BPA was bioavailable in blood in a gavage experiment with monkeys, while BPA fed in a piece of fruit resulted in over 7 percent of administered BPA being bioavailable in blood.
The authors point out that while "all dosing methods have pros and cons that must be considered in the design of a study," recent studies suggest that gavage may interfere with the study of EDCs and viable alternatives do exist. EDCs and drugs can be administered by milling a compound into feed, dissolving it in drinking water, feeding animals from a pipette or adding a compound to a wafer or other food. Also, implanted devices and osmotic pumps "are of particular interest in BPA studies because they can provide constant exposures to low doses that produce serum concentrations that approximate those found in humans. These routes of exposure may be relevant also because there are important and significant non-oral sources of BPA exposure," Vandenberg and colleagues state.
- University of Massachusetts
- risk assessment
- oral gavage
- endocrine disruptin…
In the largest study to date on phthalates and postmenopausal breast cancer, a University of Massachusetts Amherst cancer epidemiology researcher found no association between breast cancer risk and exposure to the plasticizing and solvent chemicals used in such common products as shampoo, m ... more
In a study, environmental scientists led by Laura Vandenberg at the University of Massachusetts Amherst report that they observed changes in mammary gland development of female mice exposed during early development to the chemicals used in unconventional oil and gas (UOG) extraction - inclu ... more
- 1analytica 2020: World’s leading trade fair to be held virtually
- 2Portable, point-of-care COVID-19 test could bypass the lab
- 3analytica 2020: The world’s leading trade fair extends its reach with analytica virtual
- 4Researchers dramatically downsize technology for fingerprinting drugs and other chemicals
- 5Attacking tumours directly on identification
- 6Towards a cell-based interceptive medicine in Europe
- 7A tiny instrument to measure the faintest magnetic fields
- 8Giant nanomachine aids the immune system
- 9Leap forward in the fight against antibiotic resistance
- 10New device can measure toxic lead within minutes
- Blood-based test accurately identifies viral infection before symptoms develop
- Method to safely study COVID-19, other contagious diseases developed
- QIAGEN fully acquires NeuMoDx Molecular
- Bruker Announces Acquisition of Canopy Biosciences, LLC
- Portable, point-of-care COVID-19 test could bypass the lab